Effect of anticoagulants, vasodilators, and dipyridamole on postischemic cerebral vascular obstruction.
D000605:Amino Alcohols / Q000627:therapeutic use; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000209:etiology / Q000517:prevention & control*; D004176:Dipyridamole / Q000627:therapeutic use*; D005021:Ethylamines / Q000627:therapeutic use; D005341:Fibrinolysin / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D002546:Ischemic Attack, Transient / Q000150:complications*; D010208:Papaverine / Q000627:therapeutic use; D010636:Phenols / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011817:Rabbits; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
D000605:Amino Alcohols; D000925:Anticoagulants; D001639:Bicarbonates; D005021:Ethylamines; D010636:Phenols; D011725:Pyridines; D014665:Vasodilator Agents; D014859:Warfarin; D004176:Dipyridamole; D006493:Heparin; D010208:Papaverine; D005341:Fibrinolysin